India approves Johnson & Johnson COVID-19 vaccine for emergency use

Johnson & Johnson’s single-dose COVID-19 vaccine has received emergency use approval in India, health minister Mansukh Mandaviya said in a tweet. 

The US pharmaceutical giant had applied for emergency use approval of its vaccine, the company had said on Friday. With this, India adds 5 vaccines to the approved list. The other four are Serum Institute’s Covishield, Bharat Biotech’s Covaxin, Russia’s Sputnik V, and Moderna.

The shot will be brought to India through a supply agreement with homegrown vaccine maker Biological E Ltd, J&J had said.

Read also: Sputnik; Russia in talks with Kerala government on vaccine manufacture facility

“We are pleased to announce that on 7th August 2021, the Government of India issued Emergency Use Authorization (EUA) for the Johnson & Johnson COVID-19 single-dose vaccine in India, to prevent COVID in individuals 18 years of age and older,” a Johnson & Johnson India spokesperson said.

Studies have shown that the Johnson & Johnson vaccine is 66 percent effective in preventing cases of moderate to severe illness and 85 percent effective against severe cases of COVID-19. It completely prevented hospitalizations and death four weeks after inoculation, according to studies.

Leave a Reply

Your email address will not be published.